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A B S T R A C T
We recently reported that rodent hippocampal slices incubated with levetiracetam for 3 h had altered
responses to repetitive stimulation and reduced neurotransmitter release. However, our experiments
failed to determine the actual time course of diminished transmission in individual slices followed over
time. We have now been able to record from the same slices for up to 3 h to determine the latency of the
levetiracetam effect after the onset of exposure. Within 30 min of levetiracetam exposure, the later ﬁeld
potentials of a burst were reduced. Between 60 and 180 min the relative size of later ﬁeld potentials
remained stable. Similar time-dependent reductions were not seen in control slices or in slices exposed
to the inactive levetiracetam isomer UCB L060. These new results establish a clear time dependence of
the levetiracetam effect, even in vitro, and are best explained by levetiracetam acting within neurons to
alter synaptic vesicle release.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journal homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
Although levetiracetam (LEV) has been available since 1999 as
an antiepileptic drug, its mechanism of action has not been
conclusively elucidated. There is some evidence LEV can affect a
variety of ligand- and voltage-gated neuronal channels, but the
evidence for this is not compelling. However, biochemical data
quite convincingly demonstrate that LEV speciﬁcally binds to the
presynaptic vesicle protein SV2A.1 Very recent data even
correlate LEV’s efﬁcacy as an antiepileptic with the presence of
the SV2A protein: mice heterozygous for an SV2A knockout were
less sensitive to the antiepileptic effect of LEV in various
experimental epilepsy models.2 To date, however, there has
been a dearth of neurophysiological evidence consistent with a
presynaptic locus for LEV’s antiepileptic effect. We previously
demonstrated a very noticeable effect of LEV on synaptic
transmission and presynaptic vesicle release. These results
utilized data obtained from separate populations of hippocampal
slices incubated for different periods of time in the presence or
absence of LEV, and its inactive isomer UCB L060.3 These
experiments did not allow us to determine the latency of onset* Corresponding author at: Department of Pediatrics (Clinical Neuroscience),
University of Minnesota Medical School - MMC 486, 420 Delaware Street S.E.,
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1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.07.004of LEV action, nor did they allow us to continually examine
physiological properties in the same brain slices.
Because the accurate determination of LEV onset is an
extremely important issue for clinical use, we serially assessed
synaptic physiology in the same slices in order to more precisely
determine when the LEV’s effect manifests and to try to verify our
earlier physiological observations.
2. Methods
2.1. Animals and hippocampal slice preparation
Four- to six-week-old male Sprague–Dawley rats were used for
all experiments. Care and use of animals conformed to a protocol
approved by the University of Minnesota Institutional Animal Care
and Use Committee. The rats were anesthetized with halothane
and rapidly decapitated. The brains were removed and brieﬂy
immersed in ice-cold artiﬁcial cerebrospinal ﬂuid (ACSF) contain-
ing (mM): 124 NaCl, 5 KCl, 2 CaCl2, 2 MgSO4, 1.25 NaH2PO4, 22
NaHCO3, and 10 glucose, and continuously bubbled with a 95% O2/
5% CO2 gas mixture. They were then placed on their dorsal surface
on ACSF-dampened ﬁlter paper. The cerebellum and brain stem
were removed with a scalpel, and the portion of the brain anterior
to the optic chiasm was removed with one coronal cut. The ﬂat
frontal surface was then rotated down, and the ventral surface was
placed against an agarose block in a vibratome pan (Pelco, St. Louis,
MO, USA). The pan was ﬁlled with oxygenated ice-cold ACSF, and
the vibratome well was ﬁlled with ice water. We cut 500mMvier Ltd. All rights reserved.
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excursion speed that allowed the blade to pass in 20–30 s. The
hemispheres of each slice were separated and incubated in a
submerged, oxygenated holding chamber (BSC-PC, Warner Instru-
ments, Hamden, CT, USA) at 25 8C for 1–3 h before transfer to a
recording chamber.
2.2. Electrophysiology experiments
Electrophysiological recordings were made in a submerged
chamber (RC-26G, Warner Instruments) perfused with oxyge-
nated control ACSF or ACSF containing LEV or UCB L060. Perfusion
rate was 2 ml min1 and the inﬂow was heated to 33 8C (SH-27B,
Warner). All chemicals mentioned below were dissolved in ACSF.
Our recording microelectrodes were made from 1.2 o.d./0.68 i.d.
(mm) borosilicate glass (WPI, Sarasota, FL, USA) and had
resistances of 4–6 MV when ﬁlled with ACSF. A constant current
stimulator (WPI 305) delivered pulses in stratum radiatum of CA3
through a bipolar tungsten microelectrode (SNEX-200X; Rhodes
Medical Instruments, Summerland, CA, USA). At the start of
experiments, an input–output curve was established for the
amplitude of the ﬁeld EPSP (fEPSP), from which half-maximal
stimulation intensity was determined. This stimulation strength
was used for the remainder of the recording session and varied byFig. 1. Effect of repetitive stimulation on CA1 ﬁeld potentials in single slices exposed to
potentials in a burst over the interval from baseline (A1) through 30 min (A2), 60 min (A
and 180 min (B2) in the presence of UCB L060 (100mM). (C) In control ACSF, therewas als
scales apply to (A)–(C). The 1.0 mV calibration refers to the traces in C only. The vertical b
horizontal red arrow in (A1) points to a stimulus artifact. In some traces the stimulusapproximately twofold from slice to slice. Field potentials from
the dendritic layer of CA1 were fed into a conventional DC
ampliﬁer (Axoclamp 2A; Axon Instruments, Union City, CA, USA),
digitized at 1 kHz, and stored on a personal computer using a
commercially available A/D converter and software (Digidata
1200 and pClamp 9; Axon Instruments). The magnitude of
individual ﬁeld potentials was measured between onset and
peak negative deﬂection (Fig. 1A). To determine the effects of LEV
and UCB L060, we delivered three trains of 20 stimuli (40 Hz),
separated by 1 min, and averaged the three. We repeated this
sequence every 30 min for 3 h and calculated the ratio of the ‘‘n’’th
to the ﬁrst postsynaptic potential (EPSPn/EPSP1). Normalizing the
ﬁeld potentials in this way allowed us to compare responses
across different slices and experimental conditions. We limited
the number of repetitive stimulations to avoid inducing long term
potentiation.
2.3. Chemicals
All reagents were purchased from Sigma (St. Louis, MO)
except for 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), which
was purchased from Tocris Bioscience (Ellisville, MO, USA) and
LEV and UCB L060 which were both supplied by UCB SA,
Belgium.LEV, UCB L060, and control ACSF. (A) LEV (100mM) diminished the later synaptic
3) and 180 min (A4). (B) Synaptic potentials did not decrease between baseline (B1)
o no difference in ﬁeld potentials between 0 (C1) and 180 min (C2). Voltage and time
lue line in (A1) (red arrow) illustrates the amplitudemeasurement of the EPSPs; the
artifact was cut off to limit the size of the ﬁgure.
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3.1. Effect of LEV on repetitive stimulation
In the presence of LEV (100mM), therewas a clear decrement in
the size of repetitive ﬁeld potentials over the interval from 30 min
to 3 h (Fig. 1A). In the actual raw traces of the 0.5 s 40 Hz bursts,Fig. 2. (A) Normalized, averaged ﬁeld potentials in slices (n = 6) exposed to LEV and
repetitively stimulated three times every 30 min for 3 h. There is a clear, time-
dependent and impulse-dependent effect of LEV exposure on the normalized
repetitive ﬁeld potentials. There were no signiﬁcant differences between individual
values of EPSP2/EPSP1, EPSP3/EPSP1 and EPSP4/EPSP1 between 0 min and the other
times (a–c; p > 0.05 by Student–Newman–Keuls multiple comparison test
following Friedman Repeated Measures Analysis of Variance on Ranks).
However, there was a signiﬁcant difference in the later values of normalized
EPSPs over time. For example, EPSP5/EPSP1, EPSP15/EPSP1 and EPSP20/EPSP1 were
signiﬁcantly greater at 0 min, compared to 30–180 min (d–f; p < 0.05 by Student–
Newman–Keuls test following Friedman Repeated Measures Analysis of Variance
on Ranks). (B) The inactive LEV isomer, UCB L060 had no effect on repetitive
stimulation. In fact, as duration of exposure increased, the normalized ﬁeld
potential amplitudes in the stimulus train actually increased (n = 6 slices). (C)
Control slices (n = 6) thatwere not exposed to any drug alsomaintained a consistent
relative normalized ﬁeld potential value. As with UCB L060, the normalized ﬁled
potentials slightly increased over time. In (A)–(C), error bars are standard deviations.
They are only shown for times 0 and 180 because showing all error bars would
produce excessive overlap.this decrement was apparent by 30 min, and in the normalized
ﬁeld potentials becamemore evident during later responseswithin
the bursts (Fig. 2A). For example, there was no signiﬁcant
decrement in EPSP2/EPSP1 or EPSP4/EPSP1 over the 0–180 min
time interval (p = 0.2 and 0.1, respectively, by Friedman Repeated
Measures Analysis of Variance on Ranks). However, there was a
signiﬁcant difference in EPSP5/EPSP1, EPSP15/EPSP1, and EPSP20/
EPSP1 at 0 min, compared to 30–180 min (p < 0.05 by Student–
Newman–Keuls multiple comparison test following Friedman
Repeated Measures Analysis of Variance on Ranks). We did not do
the analogous comparison on the UCB L060 (100mM) and control
groups because EPSPn/EPSP1 actually increased over time in both of
these groups (Figs. 1B and C and 2B and C). This makes it highly
unlikely that the changes in ﬁeld potentials observed over time in
LEV could be attributed to the duration of the experiment.
When we compared the amplitudes of the normalized ﬁeld
potentials over time in the LEV groups to the UCB L060 and control
groups, we also saw signiﬁcant differences that were more
apparent at the later EPSPs in the bursts (Fig. 3). At time 0, as
expected neither the second nor twentieth normalized EPSP
differed between the three groups. At 180 min, the normalized
amplitudes of the second and third EPSPs were also not
signiﬁcantly different among LEV, UCB L060, and control. However,
the normalized amplitude of the fourth EPSP and beyond in the LEV
group, was signiﬁcantly reduced compared to UCB L060 and
control.
3.2. Alternative explanations for LEV’s effect
In addition, we were concerned that there might be a
cumulative effect of LEV on synaptic transmission that could
account for the reduction in normalized ﬁeld potentials during
repetitive stimulation. We, therefore, plotted the absolute value of
the initial ﬁeld potentials in control slices and slices exposed to LEV
and UCB L060 (Fig. 4A). There was no progressive decline in initial
ﬁeld potential amplitudes in any of the three experimental
conditions. With LEV exposure, there was actually a small, but
statistically insigniﬁcant, increase in the initial ﬁeld potentials over
the 3 h observation period. Our observations with LEV duringFig. 3. Time- and stimulus-dependent effect of LEV compared to UCB L060 and
control. At 0 min, the amplitude of the second and twentieth normalized EPSP in
LEV (n = 6) did not signiﬁcantly differ from the UCB L060 (n = 6) and control groups
(n = 6) (a, p > 0.05 by Student–Newman–Keuls). At 180 min, the amplitude of the
second EPSP and third EPSP in LEV still did not signiﬁcantly differ from UCB L060
and control (a, p > 0.05 by Student–Newman–Keuls). However, the fourth, tenth,
and twentieth EPSPs in the LEV group become progressively smaller relative to the
EPSPs in the UCB L060 and control groups (b, p < 0.05 by Student–Newman–Keuls).
Fig. 4. (A) LEV did not reduce the initial ﬁeld potential in the stimulus train over
time. Although comparing the absolute values of ﬁeld potentials is difﬁcult, there is
no direct evidence here that LEV depletes the neurotransmitter pool over time (n = 6
slices). (B) CNQX, an antagonist of the AMPA subtype of glutamate receptors
achieves steady-state block of ﬁeld potentials within 30 min (n = 5 slices). Thus, the
prolonged latency observed with LEV is unlikely to be explained by delayed slice
diffusion.
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depressing transmission.
The effect of LEV on transmission did not reach a steady-state
until 1 h (Fig. 2A). It is possible that a requirement for LEV to
actually cross the neuronal cell membrane accounts for this long
latency, but another possibility was that our perfusion conﬁgura-
tion led to a delay in drug entry into the slice. In order to test this
hypothesis, we looked at the kinetics of AMPA receptor block by
the competitive AMPA receptor antagonist 6-cyano-7-nitroqui-
noxaline-2,3-dione (CNQX). CNQX acts at the plasma membrane
and does not require entry into the cell. At a subsaturating
concentration of 1mM, steady-state CNQX inhibition of ﬁeld
potentials was seen between 20 and 30 min (Fig. 4B). This suggests
that slice penetration alone cannot explain the delay in LEV
inhibition of repetitive ﬁeld potentials.
4. Discussion
Our new experiments support and extend prior results showing
a stimulus-dependent effect of LEV on synaptic transmission and
document a substantial delay before LEV exerts its full physiolo-
gical effect even in a relatively simple in vitro physiological
preparation.3 We believe that this is the ﬁrst set of in vitro
physiology experiments to serially examine synaptic transmission
in the same slices over a prolonged time course. Our previous slice
observations documented that incubation of hippocampal slices in
LEV for 3 h led to reduction of repetitive synaptic potentials and a
concomitant decrease in vesicular release measured by FM1-43
destaining. We suggested that the failure of others to detect LEV’s
effect on transmissionwas probably due to an inadequate period ofobservation. The current results substantiate that explanation.
Moreover, they show that looking only at single synaptic responses
would probably have led to erroneous conclusions, because LEV’s
inﬂuence on transmission becomes more evident when serial
responses are monitored. Our results document that LEV did not
diminish the initial amplitude of the ﬁeld potentials over time,
conﬁrming that the drug has a selective inﬂuence on repetitive
synaptic transmission or burst discharges, which may account for
its efﬁcacy as an antiepileptic drug.
Our results are compatible with biochemical observations that
LEV speciﬁcally and selectively binds a presynaptic vesicle protein,
SV2A.1 Since this protein resides within an intracellular compart-
ment, LEV must also have to enter the neuron in order to inﬂuence
synaptic transmission. CNQX, which acts on glutamate receptors
on the neuronal surface and has a higher molecular weight (232 vs
170) and lowerwater solubility than LEV, exerts amore rapid effect
than LEV, implying that the perfusion speed used in these
experiments and slice penetration cannot account for the latency
of the LEV’s effect.
Although the neurobiology SV2A has been extensively studied
in mice lacking the protein, the precise function of the protein in
normal transmission has still not been elucidated.4–7 Work on
cultured neurons lacking SV2A initially suggested that the protein
somehow increased the size of the readily releasable pool of
neurotransmitter.6 More recent tissue culture observations have
conﬁrmed an SV2A effect on synaptic release, but suggest it
enhances vesicle sensitivity to calcium and synaptotagmin.7 The
observation by at least two groups that SV2A is not absolutely
necessary for synaptic transmission may provide an interesting
insight into LEV’s relative lack of clinical neurotoxicity.6,7 Even
complete binding of SV2A by high concentrations of LEVwould not
be expected to have an enormous effect on basal synaptic
neurotransmission.
Because SV2A’s fundamental role in transmission is still
undeﬁned, it is difﬁcult to propose a satisfactory explanation for
LEV’s modulation of repetitive stimulation. An cumulative effect of
LEV on either vesicular binding of calcium or the rate of depletion
of the readily releasable pool of vesicles would be compatible with
our results, but we have no direct supporting evidence to date. The
ﬁnding that SV2A is also a binding site for botulinum toxin is
fascinating, but has not provided new insights into LEV’s
antiepileptic properties.8,9 Nonetheless, it supports the notion
that interfering with SV2A will interfere with transmitter
exocytosis. It would be helpful in the future to experimentally
conﬁrm that LEV exerts it effects within the synaptic terminal. This
could be possible in cultured neurons, where ﬂuorescent dyes
could be used to compare the rates of vesicular release between
control neurons and neurons directly injected with LEV through an
intracellular pipette.
Two in vivo lines of evidence provide additional support for a
delayed onset of action of LEV, compatiblewith an intracellular site
of action. First, some accounts of successful treatment of status
epilepticus with intravenous levetiracetam report a much longer
latency to seizure cessation than when status is aborted with
benzodiazepines.10,11 Second, Epstein et al. found a substantial
latency between peak serum levels of LEV and suppressive effects
of LEV on transcranial magnetic stimulation thresholds in
volunteers who had received a single loading dose of LEV.12 Their
result is best explained by LEV exerting its physiological effect in a
body compartment removed from the extracellular space.
Our results, taken together with these other reports, strongly
support the unique properties of LEV. Moreover, the development
of two new LEV analogs with higher SV2A afﬁnity, brivaracetam
and seletracetam, indicates that SV2A will remain a compelling
target for new antiepileptic drug development.13,14 We believe
that more rigorous neurobiological investigation of LEV will
X.-F. Yang, S.M. Rothman / Seizure 18 (2009) 615–619 619suggest even more imaginative strategies for designing new
antiepileptic drugs.
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